| (1) |
Daniels GH. Thyroid nodules and nodular thyroids: a clinical overview.
Compr Ther. 1996; 22: 239-50. |
| (2) |
Smith SA, Gharib H. Thyroid nodule suppression. Advances in Endocrinology
and Metabolism. 1991; 2: 107-24. |
| (3) |
Cooper DS. Clinical review 66: thyroxine suppression therapy for benign
nodular disease. J Clin Endocrinol Metab. 1995; 80: 331-4. |
| (4) |
Burch HB. Evaluation and management of the solid thyroid nodule. Endocrinol
Metab Clin North Am. 1995; 24: 663-710. |
| (5) |
Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between
palpation and ultrasonography. Arch Intern Med. 1995; 155: 2418-23. |
| (6) |
Rojeski MT, Gharib H. Nodular thyroid disease. Evaluation and management.
N Engl J Med. 1985; 313: 428-36. |
| (7) |
Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med.
1993; 328: 553-9. |
| (8) |
Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages,
limitations, and effect. Mayo Clin Proc. 1994; 69: 44-9. |
| (9) |
Rolla AR. Thyroid nodules in the elderly. Clin Geriatr Med. 1995; 11:
259-69. |
| (10) |
Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence
by palpation and ultrasonography. Arch Intern Med. 1994; 154: 1838-40. |
| (11) |
Mazzaferri EL, de los Santos ET, Rofagha-Keyhani S. Solitary thyroid nodule:
diagnosis and management. Med Clin North Am. 1988; 72: 1177-211. |
| (12) |
Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et
al. Cancer risk in patients with cold thyroid nodules: relevance of iodine
intake, sex, age, and multinodularity. Am J Med. 1992; 93: 363-9. |
| (13) |
McCall A, Jarosz H, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma
in solitary cold nodules and in multinodular goiters. Surgery. 1986; 100:
1128-32. |
| (14) |
Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in
the haystack [Editorial]. Am J Med. 1992; 93: 359-62. |
| (15) |
Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable
nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;
126: 226-31. |
| (16) |
Blum M. Why do clinicians continue to debate the use of levothyroxine
in the diagnosis and management of thyroid nodules? [Editorial] Ann Intern
Med. 1995; 122: 63-4. |
| (17) |
Giuffrida D, Gharib H. Controversies in the management of cold, hot, and
occult thyroid nodules. Am J Med. 1995; 99: 642-50. |
| (18) |
Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an
appraisal. Ann Intern Med. 1993; 118: 282-9. |
| (19) |
Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of
the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med. 1993;
13: 699-709. |
| (20) |
Caruso D, Mazzaferri EL. Fine needle aspiration biopsy in the management
of thyroid nodules. Endocrinologist. 1991; 1: 194-202. |
| (21) |
DeGroot LJ. Clinical review 2: diagnostic approach and management of patients
exposed to irradiation to the thyroid. J Clin Endocrinol Metab. 1989; 69:
925-8. |
| (22) |
Ito M, Yamashita S, Ashizawa K, Namba H, Hoshi M, Shibata Y, et al. Childhood
thyroid diseases around Chernobyl evaluated by ultrasound examination and
fine needle aspiration cytology. Thyroid. 1995; 5: 365-8. |
| (23) |
Boey J, Hsu C, Collins RJ. False-negative errors in fine-needle aspiration
biopsy of dominant thyroid nodules: a prospective follow-up study. World
J Surg. 1986; 10: 623-30. |
| (24) |
Grant CS, Hay ID, Gough IR, McCarthy PM, Goellner JR. Long-term follow-up
of patients with benign thyroid fine-needle aspiration cytologic diagnoses.
Surgery. 1989; 106: 980-5. |
| (25) |
Ross DS. Thyroid hormone suppressive therapy of sporadic nontoxic goiter.
Thyroid. 1992; 2: 263-9. |
| (26) |
Morita T, Tamai H, Ohshima A, Komaki G, Matsubayashi S, Kuma K, et al.
Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentrations
during thyroxine therapy in patients with solitary thyroid nodules. J Clin
Endocrinol Metab. 1989; 69: 227-30. |
| (27) |
Celani MF, Mariani M, Mariani G. On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid, thyroid nodules. Acta Endocrinol (Copenh). 1990; 123: 603-8. |
| (28) |
Kuo SW, Hu CA, Pei D, Ni KB, Shian LR. Efficacy of thyroxine-suppressive
therapy and its relation to serum thyroglobulin levels in solitary nontoxic
thyroid nodules. J Formos Med Assoc. 1993; 92: 55-60. |
| (29) |
Celani MF. Levothyroxine suppressive therapy in the medical management
of nontoxic benign multinodular goiter. Exp Clin Endocrinol. 1993; 101:
326-32. |
| (30) |
Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA.
Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind
controlled clinical study. N Engl J Med. 1987; 317: 70-5. |
| (31) |
Cheung PS, Lee JM, Boey JH. Thyroxine suppressive therapy of benign solitary
thyroid nodules: a prospective randomized study. World J Surg. 1989; 13:
818-21. |
| (32) |
Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison
of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic
non-toxic goitre. Lancet. 1990; 336: 193-7. |
| (33) |
Diacinti D, Salabe GB, Olivieri A, D'Erasmo E, Tomei E, Lotz-Salabe H,
et al. [Efficacy of L-thyroxine (L-T4) therapy on the volume of the thyroid
gland and nodules in patients with euthyroid nodular goiter]. Minerva Med.
1992; 83: 745-51. |
| (34) |
Reverter JL, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A. Suppressive
therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol
(Oxf). 1992; 36: 25-8. |
| (35) |
Papini E, Bacci V, Panunzi C, Pacella CM, Fabbrini R, Bizzarri G, et al.
A prospective randomized trial of levothyroxine suppressive therapy for
solitary thyroid nodules. Clin Endocrinol (Oxf). 1993; 38: 507-13. |
| (36) |
La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine
and potassium iodide are both effective in treating benign solitary solid
cold nodules of the thyroid. Ann Intern Med. 1995; 122: 1-8. |
| (37) |
Mainini E, Martinelli I, Morandi G, Villa S, Stefani I, Mazzi C. Levothyroxine
suppressive therapy for solitary thyroid nodule. J Endocrinol Invest. 1995;
18: 796-9. |
| (38) |
La Rosa GL, Ippolito AM, Lupo L, Cercabene G, Santonocito MG, Vigneri
R, et al. Cold thyroid nodule reduction with L-thyroxine can be predicted
by initial nodule volume and cytological characteristics. J Clin Endocrinol
Metab. 1996; 81: 4385-7. |
| (39) |
Kuma K, Matsuzuka F, Kobayashi A, Hirai K, Morita S, Miyauchi A, et al.
Outcome of long standing solitary thyroid nodules. World J Surg. 1992; 16:
583-7. |
| (40) |
Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated
benign thyroid nodules: results of long-term follow-up. World J Surg. 1994;
18: 495-8. |
| (41) |
Schneider AB, Recant W, Pinsky SM, Ryo UY, Bekerman C, Shore-Freedman
E. Radiation-induced thyroid carcinoma. Clinical course and results of therapy
in 296 patients. Ann Intern Med. 1986; 105: 405-12. |
| (42) |
Stockwell RM, Barry M, Davidoff F. Managing thyroid abnormalities in adults
exposed to upper body irradiation in childhood: a decision analysis. Should
patients without palpable nodules be scanned and those with scan defects
be subjected to subtotal thyroidectomy? J Clin Endocrinol Metab. 1984; 58:
804-12. |
| (43) |
Fogelfeld L, Wiviott MB, Shore-Freedman E, Blend M, Bekerman C, Pinsky
S, et al. Recurrence of thyroid nodules after surgical removal in patients
irradiated in childhood for benign conditions. N Engl J Med. 1989; 320:
835-40. |
| (44) |
Persson CP, Johansson H, Westermark K, Karlsson FA. Nodular goiter-is
thyroxine medication of any value? World J Surg. 1982; 6: 391-6. |
| (45) |
Berglund J, Bondesson L, Christensen SB, Larsson AS, Tibblin S. Indications
for thyroxine therapy after surgery for nontoxic benign goitre. Acta Chir
Scand. 1990; 156: 433-8. |
| (46) |
Geerdsen JP, Frolund L. Recurrence of nontoxic goitre with and without
postoperative thyroxine medication. Clin Endocrinol (Oxf). 1984; 21: 529-33. |
| (47) |
Geerdsen JP, Frolund L. Thyroid function after surgical treatment of nontoxic
goitre. A randomized study of postoperative thyroxine administration. Acta
Med Scand. 1986; 220: 341-5. |
| (48) |
Hegedus L, Hansen JM, Veiergang D, Karstrup S. Does prophylactic thyroxine
treatment after operation for non-toxic goitre influence thyroid size? Br
Med J (Clin Res Ed). 1987; 294: 801-3. |
| (49) |
Bistrup C, Nielsen JD, Gregersen G, Franch P. Preventive effect of levothyroxine
in patients operated for non-toxic goitre: a randomized trial of one hundred
patients with nine years follow-up. Clin Endocrinol (Oxf). 1994; 40: 323-7. |
| (50) |
Mccoli P, Antonelli A, Iacconi P, Alberti B, Gambuzza C, Baschieri L.
Prospective, randomized, double-blind study about effectiveness of levothyroxine
suppressive therapy in prevention of recurrence after operation: result
at the third year of follow-up. Surgery. 1993; 114: 1097-101. |
| (51) |
Wartofsky L. Does replacement thyroxine therapy cause osteoporosis? Advances
in Endocrinology and Metabolism. 1993; 4: 157-75. |
| (52) |
Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term L-thyroxine
therapy is associated with decreased hip bone density in premenopausal women.
JAMA. 1988; 259: 3137-41. |
| (53) |
Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss
in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med. 1990;
113: 265-9. |
| (54) |
Kung AW, Pun KK. Bone mineral density in premenopausal women receiving
long-term physiological doses of levothyroxine. JAMA. 1991; 265: 2688-91. |
| (55) |
Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol (Oxf). 1992; 36: 511-7. |
| (56) |
Foldes J, Tarjan G, Szathmari M, Varga F, Krasznai I, Horvath C. Bone
mineral density in patients with endogenous subclinical hyperthyroidism:
is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf).
1993; 39: 521-7. |
| (57) |
Faber J, Galloe AM. Changes in bone mass during prolonged subclinical
hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol.
1994; 130: 350-6. |
| (58) |
Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone
mineral density in elderly women. Effects of estrogen. JAMA. 1994; 271:
1245-9. |
| (59) |
Duncan WE, Chang A, Solomon B, Wartofsky L. Influence of clinical characteristics
and parameters associated with thyroid hormone therapy on the bone mineral
density of women treated with thyroid hormone. Thyroid. 1994; 4: 183-90. |
| (60) |
Wartofsky L. Levothyroxine therapy and osteoporosis. An end to the controversy?
Arch Intern Med. 1995; 155: 1130-1. |
| (61) |
Leese GP, Jung RT, Guthrie C, Waugh N, Browning MC. Morbidity in patients
on L-thyroxine: a comparison of those with a normal TSH to those with a
suppressed TSH. Clin Endocrinol (Oxf). 1992; 37: 500-3. |
| (62) |
Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose
requirements for thyrotropin suppression in the treatment of differentiated
thyroid cancer. J Clin Endocrinol Metab. 1992; 75: 344-50. |
| (63) |
Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart.
Circulation. 1993; 87: 1435-41. |
| (64) |
Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, et al. Cardiac
effects of long term thyrotropin-suppressive therapy with levothyroxine.
J Clin Endocrinol Metab. 1993; 77: 334-8. |
| (65) |
Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin
content of the heterotopically transplanted rat heart. J Clin Invest. 1986;
77: 1694-8. |
| (66) |
Klein I. Thyroid hormone and the cardiovascular system. Am J Med. 1990;
88: 631-7. |
| (67) |
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al.
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation
in older persons. N Engl J Med. 1994; 331: 1249-52. |
| (68) |
Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, et al.
Control of adrenergic overactivity by beta-blockade improves the quality
of life in patients receiving long term suppressive therapy with levothyroxine.
J Clin Endocrinol Metab. 1994; 78: 1028-33. |